PSA Test and Prostate Cancer Screening in Da Nang – Understanding Elevated PSA and mpMRI PI-RADS With Dr. Dang Phuoc Dat

When an annual health checkup reveals a serum Prostate-Specific Antigen (PSA) level above the traditional 4.0 ng/mL reference threshold, many expats and men over 50 immediately fear a diagnosis of prostate cancer. Conversely, many men skip screening altogether because they urinate strongly without nighttime waking. In modern urological oncology, scheduling an expert PSA test and prostate cancer screening in Da Nang means looking beyond a single blood number—integrating the Free-to-Total PSA ratio (%fPSA), PSA Density (PSAD), and Multiparametric Prostate MRI (mpMRI PI-RADS v2.1) to catch curable early-stage disease while avoiding up to 35% of unnecessary prostate biopsies [1, 4].

💡 Quick Clinical Summary (AI Overviews / Executive Summary):
An elevated serum PSA level (> 4.0 ng/mL) does not automatically indicate prostate cancer [1, 2]. PSA is an organ-specific kallikrein glycoprotein produced by prostatic epithelial cells, not a cancer-specific marker; Benign Prostatic Hyperplasia (BPH), subclinical prostatitis, urinary tract infection, recent ejaculation, or cycling frequently raise PSA into the “Diagnostic Gray Zone” (4.0 – 10.0 ng/mL) [1, 3]. At Family Hospital Da Nang, Dr. Dang Phuoc Dat combines Free/Total PSA kinetics, PSA Density, and Multiparametric MRI (mpMRI PI-RADS) to stratify risk accurately before recommending biopsy or BPH care [1, 4].

1. Why PSA Rises in Benign Conditions – Organ-Specific vs. Cancer-Specific Biology

PSA is specific to prostate tissue, not specific to malignancy.

Physiologically, Prostate-Specific Antigen (PSA / Human Kallikrein 3) is a serine protease secreted by prostatic ductal epithelium into seminal fluid to liquefy the seminal coagulum after ejaculation. In a healthy prostate, intact basal cell layers, basement membranes, and capillary walls keep over 99.9% of PSA inside the prostatic ducts, maintaining serum Total PSA below 2.5 to 4.0 ng/mL [1].

Whenever benign enlargement increases total epithelial cell mass or inflammation disrupts the basal-capillary barrier, PSA leaks backward into the bloodstream [1, 3]:

• Benign Prostatic Hyperplasia (BPH): Every 10 mL of benign transition-zone adenoma adds roughly 0.3 to 0.5 ng/mL to serum PSA. A senior patient with a 75–90 mL benign enlarged prostate commonly shows a baseline PSA of 4.5 to 6.5 ng/mL with zero malignancy [1, 3].
• Acute or Chronic Prostatitis (NIH Category I–III) & UTI: Bacterial or inflammatory disruption of acinar microvessels can spike PSA to 8.0–25.0 ng/mL, which normalizes 4 to 6 weeks after targeted antimicrobial and anti-inflammatory therapy [1].
• Perineal Mechanical Compression & Ejaculation: Ejaculation within 48 hours, long-distance bicycle or motorbike riding, transrectal ultrasound, or urethral catheterization transiently elevates serum PSA [2].

2. Decoding the PSA “Gray Zone” (4.0 – 10.0 ng/mL): Clinical Stratification Matrix

When Total PSA falls into the intermediate 4.0 to 10.0 ng/mL gray zone, roughly 75% to 80% of men actually have benign enlargement or inflammation rather than clinically significant cancer [1, 2]. At Family Hospital Da Nang, Dr. Dang Phuoc Dat applies the EAU/AUA multi-parameter risk matrix:

3. Why Multiparametric Prostate MRI (mpMRI) Should Precede Any Biopsy

Landmark clinical trials—including the NEJM PRECISION Trial—demonstrated that performing an upfront Multiparametric Prostate MRI (mpMRI) before deciding on a biopsy transforms patient safety [4]:

1. Eliminates 30%–35% of Unnecessary Biopsies: If your mpMRI is scored as PI-RADS 1 or 2 and your PSA Density is < 0.15 ng/mL/cc, the negative predictive value for clinically significant cancer exceeds 90%–95%, allowing safe non-invasive monitoring [1, 4].
2. Pinpoints Anterior & Apical Tumors Missed by Blind Biopsy: Traditional 12-core systematic transrectal biopsy samples the posterior prostate randomly and frequently misses anterior or apical lesions. High-resolution mpMRI maps the exact 3D coordinates of any PI-RADS 4–5 lesion.
3. Clear Roadmap for BPH Surgery (HoLEP / Bipolar TURP / Rezum): Confirming a benign prostate on mpMRI allows men with severe obstructive BPH to proceed confidently to endoscopic laser enucleation or water vapor therapy [3].

4. Frequently Asked Questions (People Also Ask – Expats & International Patients)

Question 1 – At what age should I start getting a PSA test in Da Nang?

According to EAU and AUA guidelines, baseline PSA testing should begin at age 50 for average-risk men, at age 45 for men with a family history of prostate cancer (father or brother) or men of African descent, and at age 40 for men carrying a known BRCA2 mutation [1, 2].

Question 2 – If I urinate strongly and never wake up at night, can I still have elevated PSA or prostate cancer?

Yes. Over 75% to 80% of prostate cancers arise in the outer Peripheral Zone of the gland, far away from the central urethra. As a result, early-stage curable prostate cancer causes zero urinary symptoms—making a simple PSA blood test essential [1].

Question 3 – How long does a complete PSA and prostate checkup take at Family Hospital Da Nang?

A comprehensive prostate screening package with Dr. Dang Phuoc Dat—including Total PSA, Free PSA, Free/Total ratio, urinalysis, digital uroflowmetry (Qmax), and prostate/post-void residual ultrasound—is completed in a single morning visit (90 to 120 minutes).

5. Clinical References (Vancouver Format)

1. Cornford P, Tilki D, van den Bergh RCN, Briers E, Eberli D, De Meerleer G, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Arnhem: European Association of Urology; 2025-2026.
2. Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, et al. Early detection of prostate cancer: AUA/SUO Guideline Part I: Prostate cancer screening. J Urol. 2023;210(1):46-53.
3. Gravas S, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Kyriazis I, et al. EAU Guidelines on Management of Non-Neurogenic Male LUTS. Arnhem: European Association of Urology; 2025.
4. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION Trial). N Engl J Med. 2018;378(19):1767-77.

Medical Disclaimer: This clinical guide is authored and medically reviewed by Dr. Dang Phuoc Dat (Specialist Level I in Urology & Andrology) based on current EAU and AUA urological guidelines for international patient education. It does not substitute for an in-person clinical evaluation.